Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Sexually transmitted disease

Antibiotic with novel mode of action effective against gonorrhoea infection

Study results show that 96% of patients taking a single 2g or 3g dose of the novel antibiotic zoliflodacin were microbiologically cured of gonorrhoea.

Neisseria gonorrhoeae bacteria

Source: CDC / Science Photo Library

Researchers found that 96% of patients taking 2g zoliflodacin, a novel antibiotic that works by preventing bacterial cells from replicating DNA, were microbiologically cured of urogenital gonorrhoea (micrograph pictured)

A novel antibiotic, which prevents bacterial cells from replicating DNA, is effective in the treatment of uncomplicated urogenital gonorrhoea, results from a phase II clinical trial have shown[1].

The trial involved 179 people who had either uncomplicated or untreated urogenital gonorrhoea, or who had sexual contact with a person with gonorrhoea in the prior 14 days. They received single-dose oral zoliflodacin (2g or 3g) or a single intramuscular injection of ceftriaxone (500mg).

A test of cure occurred within 6±2 days after treatment, followed by a safety visit 31±2 days after treatment.

It was found that 96% of patients taking 2g zoliflodacin were microbiologically cured, as were 96% of those in the 3g dose group and 100% of those in the ceftriaxone group. Most adverse events in the zoliflodacin groups were mild and gastrointestinal in nature.

“Reports of multidrug-resistant [Neisseria] gonorrhoeae and the possibility of untreatable gonorrhoea underscore the need for the development of new antimicrobial agents,” the researchers wrote in the New England Journal of Medicine (8 November 2018).

“This phase II trial creates equipoise for larger, more definitive studies of zoliflodacin.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205888

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now
  • Good Pharmacovigilance Practice Guide

    Good Pharmacovigilance Practice Guide

    An essential guide on pharmacovigilance of medicinal products for human use. Practical advice for developing effective pharmacovigilance systems.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.